Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
View Patent ↗The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.
1. A method for inhibiting proliferation or killing CD71 positive malignant tumor cells, comprising providing to a patient in need thereof
an anti-CD71 monoclonal antibody or an antigen-binding fragment thereof, wherein said anti-CD71 monoclonal antibody comprises
(a) at least one heavy chain variable region comprising the amino acid sequence of SEQ ID No. 1 and at least one light chain variable region comprising an amino acid sequence selected from the group consisting of SEQ ID No. 2 and SEQ ID No. 11; or
(b) at least one heavy chain variable region encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID No. 3 and at least one light chain variable region encoded by a nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of SEQ ID No. 4 and SEQ ID No. 12
under conditions and in an amount sufficient for the binding of said anti-CD71 monoclonal antibody to the malignant tumor cells, thereby causing inhibition of proliferation or killing of the malignant tumor cells.
2. The method according to claim 1 , wherein said malignant tumor cells are selected from cells of metastatic cutaneous melanoma, metastatic uveal melanoma, glioblastoma, renal cell carcinoma, hepatocarcinoma (HCC), ovarian adenocarcinoma, pancreas adenocarcinoma, non small cell lung carcinoma (NSCLC), breast adenocarcinoma, colorectal adenocarcinoma, and hematological malignancies.
3. The method according to claim 1 , further comprising, prior to said providing, a step of depleting intracellular transferring level and/or intracellular iron level in said malignant tumor cells.
4. A method for producing a chimeric antibody that binds CD71, comprising:
a) transforming a suitable host cell with at least one expression vector comprising two or more of the nucleotide sequences depicted in SEQ ID Nos. 3, 4, and 12;
b) culturing said host cell under conditions favoring expression; and
c) purifying assembled chimeric antibodies from the culture medium.
5. A method for producing a chimeric antibody that binds CD71, comprising:
a) transforming a suitable host cell with at least one expression vector which comprises: (i) a nucleic acid molecule comprising two or more of the nucleotide sequences depicted in SEQ ID Nos. 3, 4, and 12; and (ii) one or more of the nucleotide sequences depicted in SEQ ID Nos. 7, 8, and 10;
b) culturing said host cell under conditions favoring expression; and
c) purifying assembled chimeric antibodies from the culture medium.